Stroke in Hemodialysis Patients Randomized to Different Intravenous Iron Strategies: A Prespecified Analysis from the PIVOTAL Trial

Patrick B. Mark, Pardeep S. Jhund, Matthew R. Walters, Mark C. Petrie, Albert Power, Claire White, Michele Robertson, Eugene Connolly, Stefan D. Anker, Sunil Bhandari, Kenneth Farrington, Philip A. Kalra, Charles R.V. Tomson, David C. Wheeler, Christopher G. Winearls, John J.V. McMurray, Iain C. Macdougall, Ian Ford, and on behalf of the PIVOTAL Investigators*

Key Points
- In analysis of the PIVOTAL trial, proactive intravenous iron dosing was not associated with increased stroke risk in patients on hemodialysis.
- Risk factors for stroke included diabetes, prior stroke, higher BP, lower serum albumin, inflammation, and women.
- Mortality of stroke was high; 58% of patients with a stroke event died during follow-up compared with 23% without a stroke.

Abstract

Background
People with kidney failure treated with hemodialysis (HD) are at increased risk of stroke compared with similarly aged people with normal kidney function. One concern is that treatment of renal anemia might increase stroke risk. We studied risk factors for stroke in a prespecified secondary analysis of a randomized, controlled trial of intravenous iron treatment strategies in HD.

Methods
We analyzed data from the Proactive IV Iron Therapy in Haemodialysis Patients (PIVOTAL) trial, focusing on variables associated with risk of stroke. The trial randomized 2141 adults who had started HD <12 months earlier and who were receiving an erythropoiesis-stimulating agent (ESA) to high-dose IV iron administered proactively or low-dose IV iron administered reactively in a 1:1 ratio. Possible stroke events were independently adjudicated. We performed analyses to identify variables associated with stroke during follow-up and assessed survival following stroke.

Results
During a median 2.1 years of follow-up, 69 (3.2%) patients experienced a first postrandomization stroke. Fifty-seven (82.6%) were ischemic strokes, and 12 (17.4%) were hemorrhagic strokes. There were 34 postrandomization strokes in the proactive arm and 35 postrandomization strokes in the reactive arm (hazard ratio, 0.90; 95% confidence interval, 0.56 to 1.44; P = 0.66). In multivariable models, women, diabetes, history of prior stroke at baseline, higher baseline systolic BP, lower serum albumin, and higher C-reactive protein were independently associated with stroke events during follow-up. Hemoglobin, total iron, and ESA dose were not associated with risk of stroke. Fifty-eight percent of patients with a stroke event died during follow-up compared with 23% without a stroke.

Conclusions
In patients on HD, stroke risk is broadly associated with risk factors previously described to increase cardiovascular risk in this population. Proactive intravenous iron does not increase stroke risk.

Clinical Trial registry name and registration number: Proactive IV Iron Therapy in Haemodialysis Patients (PIVOTAL), 2013-00267-25

KIDNEY360 2: 1761–1769, 2021. doi: https://doi.org/10.34067/KID.0004272021

Due to the number of contributing authors, the affiliations are listed at the end of this article.

Correspondence: Patrick B. Mark, 126 University Place, University of Glasgow, Glasgow G12 8TA, United Kingdom. Email: patrick.mark@glasgow.ac.uk
Introduction
The estimated increased risk of stroke in patients treated with hemodialysis (HD) is approximately two to ten times higher than the risk of otherwise similarly age-matched patients from the general population, with greatest excess risk in younger people (1–4). The prevalence of “conventional” risk factors associated with increased stroke risk, such as hypertension, diabetes, older age, prior cardiovascular disease, and atrial fibrillation (AF), is high in patients treated with HD (5). Other factors specific to HD treatment, such as variation in BP and altered cerebral blood flow during dialysis, may increase stroke risk (6).

Several randomized, controlled trials (RCTs) have assessed the effect of correction of anemia with erythropoiesis-stimulating agents (ESAs) on both surrogate parameters, such as left ventricular hypertrophy, and clinical outcomes, such as cardiovascular events or need for dialysis, in patients with CKD or heart failure (7–10). The overall effect of anemia correction on stroke risk in subjects with CKD has been variable, with some trials demonstrating no excess stroke risk in the ESA treatment or higher hemoglobin group (8,9,11). However, in two of the largest placebo-controlled RCTs of anemia correction in patients with CKD with the ESA darbepoetin (7,12,13), stroke risk was elevated in the group randomized to darbepoetin to target a higher hemoglobin. This observation was statistically significant in the TREAT trial in patients with diabetes and CKD and in the subgroup of patients with CKD in the RED-HF trial, suggesting that anemia correction with ESA is associated with increased risk of stroke in patients at high vascular risk with CKD irrespective of other risk factors for stroke (7,13). However, the effect of anemia correction using high iron dosing strategies (to minimize ESA use) on future stroke risk in patients treated with HD is unknown.

The Proactive IV Iron Therapy in Haemodialysis Patients (PIVOTAL) trial was an RCT of proactive versus reactive intravenous iron therapy in patients requiring HD already treated with an ESA. The methods, the baseline characteristics of the participants (14), and the main trial results (15) have been reported elsewhere. Briefly, a high-dose proactive intravenous iron regimen resulted in lower doses of ESA being administered when compared with a low-dose iron regimen, with fewer cardiovascular events occurring in the proactive arm of the trial. In this prespecified analysis, we analyzed which factors were associated with risk of stroke. We hypothesized that proactive high-dose iron would not be associated with increased stroke risk compared with reactive low-dose iron.

Patients were randomized 1:1 to receive high-dose intravenous iron administered proactively or low-dose intravenous iron administered reactively. Ferritin concentration and transferrin saturation were measured monthly, and the results were used to determine the monthly dose of iron sucrose. In the high-dose group, 400 mg of iron sucrose was prescribed, with safety cutoff limits (ferritin >700 μg/L or transferrin saturation >40%) above which further iron was withheld until the next blood test 1 month later. Patients in the low-dose group received 0–400 mg of iron sucrose monthly to maintain ferritin ≥200 μg/L and transferrin saturation ≥20%, in line with current guidelines. The protocol required the use of an ESA in a dose sufficient to maintain hemoglobin between 100 and 120 g/L, but otherwise, patients were treated according to usual practice. BP was taken by the dialysis unit nursing staff at the dialysis unit and recorded. Investigators were asked to report cardiovascular comorbidities at baseline on an electronic patient report form.

Clinical Outcomes
The primary outcome of the trial was the composite of myocardial infarction, stroke, hospitalization for heart failure, or death from any cause analyzed as time to first event. Stroke was a prespecified secondary outcome. For this manuscript, the outcomes of time to first stroke are reported. We also analyzed recurrent stroke events to account for the cumulative burden of events over time. Finally, we examined mortality related to (initially) nonfatal stroke.

Adjudication of Stroke Events and Outcomes
All potential end points and all deaths were adjudicated by an independent committee, blinded to treatment allocation. Stroke was defined as an acute episode of neurologic dysfunction caused by focal or global brain, spinal cord, or retinal vascular injury. Full details of the adjudication criteria for stroke are listed in Supplemental Material.

Statistical Analyses
The time to first event analyses were performed in the intention-to-treat population using Cox proportional hazards regression. All analyses by treatment group allocation were adjusted for the stratification variables of vascular access, diabetes, and time on dialysis. The strategy adopted was to fit a multivariable Cox regression model for the time to first event of fatal or nonfatal stroke, fitting only potential baseline risk factors omitting laboratory variables. From this model, we identified the four factors (diabetes, systolic BP [SBP], sex, and history of stroke) that had evidence of association with outcome (P=0.05). The four baseline nonlaboratory risk factors were carried forward for inclusion in models with laboratory variables [loge(C-reactive protein [CRP]), albumin, and hemoglobin] and ESA dose. A further model was fitted with the subset of variables showing evidence of association with outcome (P=0.05).

The Kaplan–Meier method was used to estimate mortality rates and cumulative incidence functions for stroke as a time to first event, correcting for the competing risk of deaths not included in the outcome of interest. Deaths...
following a stroke are analyzed descriptively. Recurrent events were analyzed using the proportional means model of Lin et al. (16). Baseline characteristics were summary counts and percentages. P values for between-group differences on the basis of chi-squared tests/Fisher exact tests, as appropriate, are provided. Analyses were performed using SAS software version 9.4 (SAS Institute) and R version 3.6.0.

Results

Baseline Characteristics of Patients Experiencing Stroke

The PIVOTAL trial randomized 2141 patients, of which 1093 patients were allocated to the proactive high-dose group and 1048 were allocated to the reactive low-dose group. The main trial results have been presented elsewhere. To summarize, 320 (29.3%) patients in the high-dose group had a primary end point event compared with 338 (32.3%) patients in the low-dose group (hazard ratio, 0.85; 95% confidence interval [95% CI], 0.73 to 1.00; P<0.001 for noninferiority; P=0.04 for superiority) (15). During a median 2.1 years of follow-up, 69 (3.2%) patients experienced a first stroke postrandomization. Of these, 57 (82.6%) were ischemic strokes, and 12 (17.4%) were hemorrhagic strokes. Baseline characteristics of patients experiencing stroke and those who did not are shown in Table 1. The prevalence of diabetes and prior stroke was higher in those who had a stroke during follow-up. The prevalence of atrial fibrillation was higher in those who had a stroke compared with those who did not. Supplemental Table 1 notes the day of the week when the baseline BP was recorded.

Effect of Treatment Group on Stroke Incidence

There were 34 first strokes in the proactive arm and 35 first strokes in the reactive arm (hazard ratio, 0.90; 95% CI, 0.56 to 1.44; P=0.66) (Figure 1). In a recurrent event analysis considering the ten patients with two stroke events and one patient with three stroke events (total of 46 stroke events) in the proactive arm and the ten patients with two stroke events and two patients with three stroke events (total of 49 stroke events) in the reactive arm, there was no significant difference in stroke incidence between treatment groups (rate ratio, 0.88; 95% CI, 0.53 to 1.45; P=0.61) (Table 2).

Factors Associated with Risk of Stroke during the PIVOTAL Trial

In a multivariable Cox regression model analyzing the whole cohort for the time to first fatal or nonfatal stroke fitting only potential baseline risk factors, diabetes, SBP, women, and history of prior stroke were associated with stroke during follow-up (Table 3). In a further analysis including baseline laboratory variables and baseline ESA dose at the start of the trial, diabetes, SBP, women, and history of prior stroke, low serum albumin and elevated logeCRP were independent predictors of stroke (Supplemental Table 2).

In a multivariable analysis taking account of baseline risk factors with albumin, logeCRP, and hemoglobin prior to the stroke and the mean iron dose and ESA dose over the duration of the trial as time-dependent variables, the variables associated with stroke were SBP, diabetes, prior stroke, women, low serum albumin, and elevated logeCRP (Table 4).

Outcomes following Stroke

A total of 40 (58%) patients who had a stroke postrandomization subsequently died during follow-up. This compares with 475 deaths (23%) in the remaining 2072 patients who did not have a stroke. Of the 40 patients with a first stroke, three of the first strokes were fatal, and one patient died on the same day as the stroke, with cause of death given as infection. Of the remaining 36 deaths, 14 were nonstroke deaths (none within 7 days of the stroke and one within 30 days), and 22 were stroke deaths (five within 7 days of the stroke and 12 within 30 days). The Kaplan–Meier time to event curve for time to death after a stroke is given in Supplemental Figure 1.

Discussion

In the PIVOTAL trial, first stroke events occurred in 69 patients (3.2% of the entire cohort) compared with 180 fatal or nonfatal myocardial infarction events (8.4%) and 121 (5.7%) hospitalizations for heart failure (15). In this large RCT of two different strategies for iron replacement in patients on HD requiring an ESA as treatment for renal anemia, the major independent baseline risk factors for stroke were women, history of diabetes mellitus or prior stroke, and baseline higher SBP. On laboratory testing, inflammation (indicated by elevated CRP) and malnutrition (indicated by low serum albumin) were associated with increased stroke risk. Therefore, in keeping with previous observational data in this population, the major risk factors for stroke in PIVOTAL were conventional risk factors for stroke observed in the general population (17,18). Inflammation and malnutrition have been associated with stroke and reduced survival in several observational studies in patients with CKD (19–21). At baseline, patients who had a postrandomization stroke had lower hemoglobin than those who did not, although this observation was not statistically significant on time to event analyses (Table 4, Supplemental Table 2). We found no association between iron treatment allocation, hemoglobin level, total intravenous iron dose, or ESA dose and stroke risk. This is irrespective of hemoglobin rising faster initially (Supplemental Material) in the proactive treatment arm and patients in the proactive group being significantly less likely to receive blood transfusions, presumably because of the initially higher hemoglobin level over the first 12 months of the trial (15). Some observational registry data support the observation that lower hemoglobin is associated with increased risk of stroke in HD, but this has not been a consistent observation (1,22,23).

Other RCTs have reported the effect of anemia treatment regimens using ESAs in patients with CKD and/or those requiring dialysis. In an RCT in patients on incident HD, like those studied in PIVOTAL, “full” correction of anemia with epoetin alfa to a hemoglobin target of 135–145 g/L compared with a target of 95–115 g/L was associated with a significantly higher incidence of stroke (4% versus 1%;
## Table 1. Baseline characteristics of patients experiencing stroke and those who did not

| Statistic                        | (1) No Stroke | (2) Stroke | P Value (1) versus (2) | (3) Ischemic | (4) Hemorrhagic | P Value (3) versus (4) |
|----------------------------------|---------------|------------|------------------------|--------------|----------------|-----------------------|
| n                                | 2072          | 69         |                        | 57           | 12             |                       |
| Randomized to proactive          | 1059          | 34         | 49.28                  | 30           | 4              | 33.3                  |
| Sex, % men                       | 1366          | 32         | 46.4                   | 24           | 8              | 66.6                  |
| Ethnicity, % White               | 1641          | 57         | 82.61                  | 48           | 9              | 75.0                  |
| Age, yr                          | 62.7          | 65.7       | 13.4                   | 61.2         | 66.6           | ±12.2                 |
| SBP, mm Hg                       | 144.3         | 156.1      | ±25.7                  | <0.001       | 157.0          | ±27.4                 |
| DBP, mm Hg                       | 73.6          | 74.4       | ±16.1                  | 76.3         | 74.0           | ±15.7                 |
| BMI, kg/m²                       | 28.7          | 30.8       | ±7.9                   | 28.2         | 31.3           | ±8.3                  |
| Dialysis duration, mo            | 5.8           | 5.0        | 3.5                    | 5.2          | 5.9            | 3.4                   |
| Smoking, %                       | 1366          | 32         | 46.4                   | 24           | 8              | 66.6                  |
| Current                          | 240           | 9          | 13.0                   | 6            | 3              | 25.0                  |
| Former                           | 524           | 21         | 25.5                   | 17           | 4              | 33.3                  |
| Never                            | 1308          | 39         | 62.9                   | 34           | 5              | 41.7                  |
| Diabetes, %                      | 904           | 46         | 66.7                   | 38           | 8              | 66.7                  |
| Stroke baseline, %               | 165           | 11         | 15.9                   | 10           | 1              | 8.3                   |
| Myocardial infarction, %         | 175           | 9          | 13.0                   | 8            | 1              | 8.3                   |
| Heart failure, %                 | 84            | 2          | 2.9                    | 1            | 1              | 8.3                   |
| Atrial fibrillation, %           | 160           | 4          | 5.8                    | 3            | 1              | 8.3                   |
| PVD, %                           | 182           | 5          | 7.3                    | 4            | 7              | 8.3                   |
| AV fistula/graft, %              | 1222          | 35         | 50.7                   | 32           | 3              | 25.0                  |
| Primary kidney disease           | 228           | 7          | 10.1                   | 5            | 2              | 16.7                  |
| Hypertension, %                  | 677           | 35         | 50.7                   | 28           | 7              | 58.3                  |
| Diabetic nephropathy, %          | 386           | 8          | 11.6                   | 7            | 1              | 8.3                   |
| Glomerular disease, %            | 198           | 3          | 4.4                    | 2            | 3.5            | 1                     |
| Tubulointerstitial disease, %    | 139           | 8          | 11.6                   | 8            | 0              | 0                     |
| Renovascular disease, %          | 117           | 5          | 0                      | 0            | 0              | 0                     |
| Polycystic kidney disease, %     | 126           | 3          | 4.4                    | 2            | 3.5            | 1                     |
| Other, %                         | 201           | 5          | 7.3                    | 5            | 0              | 0                     |
| Hemoglobin, g/L                  | 105.7         | 100.9      | ±12.8                  | 103.3        | 100.4          | ±12.7                 |
| Albumin, g/L                     | 35.8          | 33.3       | ±5.3                   | 32.9         | 35.3           | ±4.7                  |
| log(CRP), mg/L                   | 1.86          | 2.30       | ±0.98                  | 2.08         | 2.34           | ±1.00                 |
| ESA dose, IU/wk                  | 8589          | 5500       | 9.97                   | 4917         | 9328           | 5678                  |
| Mean IV iron dose/mo, mg         | 183           | 103        | 180                    | 133          | 171            | 110,221               |

Values are numbers and percentages, means ±SD, and medians and interquartile ranges as appropriate. Tests of significance are the t, the Mann–Whitney U, the chi-squared, and the Fisher exact tests as appropriate. SBP, systolic BP; DBP, diastolic BP; BMI, body mass index; na, not applicable; PVD, peripheral vascular disease; AV, arteriovenous; CRP, C-reactive protein; ESA, erythropoiesis-stimulating agent; IU, international units; IV, intravenous.
In summary, our results provide further reassurance to the headline data of the main findings of PIVOTAL that proactive iron had a neutral effect on stroke events in addition to being overall superior to a low-dose iron regime for cardiovascular outcomes and lower ESA requirements (15). We did not see a relationship between ESA dosing in PIVOTAL and risk of stroke. Cumulatively, our results, combined with these other data from RCTs, demonstrate that overall a low hemoglobin is associated with higher stroke risk in patients with CKD and/or those requiring dialysis.

Survival after stroke for the patients on dialysis in PIVOTAL was poor, and 23 subjects (33.3% of patients with a stroke) had a recurrent stroke event. This is consistent with findings of other studies (26–28). The overall number of patients with a stroke was too small to explore factors that contributed to the poor outcomes of these patients. We did not collect data on specific therapies offered to patients in the trial who had a stroke. Other observational studies suggest that patients requiring dialysis have high functional dependence prior to stroke, and hence, poor outcomes may be inevitable (26,29). Perhaps these patients are less likely to receive interventions that may improve outcomes, such as thrombolysis, acute stroke unit care, antithrombotic therapy, and associated rehabilitation therapies (26,30). There is a limited evidence base for treatment of stroke in patients requiring dialysis, with no data from RCTs specific to those on dialysis (5,31). Reduction in kidney function has been demonstrated to be associated with poor outcomes following stroke. In the post hoc analyses of the Enhanced Control of Hypertension and Thrombolysis Stroke study comparing two thrombolysis regimes, every 10–ml/min per 1.73 m² lower eGFR was associated with an adjusted 9% increased odds of death following acute ischemic stroke (32). Current thrombolysis guidelines suggest that patients with advanced CKD, including those on dialysis, receive thrombolysis, with no specific restrictions compared with those with normal kidney function (33). Combined National Stroke and Renal Registry data from Scotland show that people treated with dialysis are less likely to be managed in an acute stroke unit following a stroke than the wider stroke population (67.4% versus 79.6%; P<0.001). Survival after stroke in the same report was significantly shorter in those on dialysis (median survival was 0.8 years on dialysis compared with 3.1 years in the non-ESKD stroke population; P<0.001) (26). The adverse outcomes following stroke in PIVOTAL emphasize the need to identify if poor outcomes are driven by inequalities of care offered (26) or an absence of evidence-based therapies for acute stroke in this population (5,26,31).

There are several limitations to this analysis and further remaining questions regarding anemia management in patients on dialysis that have not been addressed by the

| Table 2. Incidence of stroke events, including both first stroke and recurrent fatal and nonfatal stroke events |
|---|
| | All, n=2141 | Proactive, n=1093 | Reactive, n=1048 |
| Events per patient | | | |
| Patients with 0 events | 2072 (96.78%) | 1059 (96.89%) | 1013 (96.66%) |
| Patients with only 1 event | 46 (2.15%) | 23 (2.10%) | 23 (2.19%) |
| Patients with 2 events | 20 (0.93%) | 10 (0.91%) | 10 (0.95%) |
| Patients with 3 events | 3 (0.14%) | 1 (0.09%) | 2 (0.19%) |
| Total patients with at least 1 stroke | 69 | 34 | 35 |
| Patients with at least 1 stroke per 100 person-yr | 1.62 | 1.54 | 1.70 |
| Total (first and recurrent) strokes | 95 | 46 | 49 |
| Total no. of strokes per 100 person-yr | 2.22 | 2.08 | 2.38 |
PIVOTAL trial. Despite performing an RCT in over 2000 patients, we observed a small number of strokes, although the stroke incidence was similar to other cohort studies (34,35). This limits the number of variables that could be tested in multivariable analyses. The PIVOTAL trial was not designed to detect differences in stroke outcomes between groups. Although stroke incidence is relatively high in patients treated with dialysis, an RCT specifically targeting stroke as an efficacy end point would be challenging. Despite 164 (7.6%) patients having AF at baseline, we captured only four strokes in these patients and cannot comment further on AF as a risk factor for stroke in HD. The prevalence of AF was lower than reported in other HD cohorts (10%–20%) (27,36,37). As the trial was performed in patients during their first year of HD, the results may not be extrapolated to patients with a longer dialysis history. Long-term safety data on the effect of proactive iron on iron overload are required. The incidence of stroke at 2.22/100 patient-years is similar to some reports (34) but half that in other observational studies in longer-term patients on HD (2,38). Stroke risk rises over the first 90 days after HD commencement and then falls over the next year prior to rising again, so interpreting stroke risk over the first year after commencing HD is challenging (39). The intravenous iron used in PIVOTAL was iron sucrose. It is unknown if similar results would be replicated for a proactive iron dosing strategy if an alternative intravenous iron preparation was used. Less than 10% of participants were of Black ethnicity, making it challenging to extrapolate the results directly to all ethnic groups. This is important given the high incidence of stroke observed in patients on dialysis of Black or Hispanic ethnicity in the United States (38). We only collected baseline BP and do not have pre- and post-dialysis BP. Cerebral perfusion drops during dialysis, which may increase risk of stroke (6).

In conclusion, in an RCT performed in a population at high risk of vascular events, we observed no association between high-dose iron and stroke risk, despite a relatively sharper initial rise in hemoglobin in the proactive iron group (15). This contrasts with the association with higher hemoglobin and vascular risk seen in the placebo-controlled anemia correction RCTs in CKD using ESA to drive a higher hemoglobin (7,13). These observations should provide further reassurance to support the use of a

| Variable                        | Hazard Ratio (95% Confidence Interval) | P Value | Hazard Ratio (95% Confidence Interval) | P Value |
|---------------------------------|----------------------------------------|---------|----------------------------------------|---------|
| Sex, women/men                 | 2.11 (1.31 to 3.40)                    | 0.002   | 2.15 (1.34 to 3.45)                    | 0.002   |
| Diabetes, yes/no               | 2.09 (1.26 to 3.47)                    | 0.004   | 2.08 (1.25 to 3.45)                    | 0.005   |
| Stroke, yes/no                 | 1.98 (1.03 to 3.78)                    | 0.04    | 2.02 (1.06 to 3.85)                    | 0.03    |
| SBP, per 10 mm Hg              | 1.18 (1.07 to 1.30)                    | 0.001   | 1.18 (1.07 to 1.30)                    | <0.001  |
| Dialysis vintage duration, per mo | 0.87 (0.54 to 1.41)                   | 0.58    |                                        |         |
| Age, per 5 yr                  | 1.08 (0.98 to 1.19)                    | 0.10    |                                        |         |
| AF, yes/no                     | 0.78 (0.28 to 2.18)                    | 0.63    |                                        |         |
| SBP, per 10 mm Hg              | 0.78 (0.48 to 1.25)                    | 0.30    |                                        |         |
| Vascular access, graft/fistula/catheter | 0.89 (0.48 to 1.44)                | 0.64    |                                        |         |

SBP, systolic BP; AF, atrial fibrillation.

| Variable                        | Hazard Ratio (95% Confidence Interval) | P Value | Hazard Ratio (95% Confidence Interval) | P Value |
|---------------------------------|----------------------------------------|---------|----------------------------------------|---------|
| Sex, women/men                 | 2.14 (1.33 to 3.45)                    | 0.002   | 2.15 (1.34 to 3.47)                    | 0.002   |
| Stroke, yes/no                 | 1.98 (1.03 to 3.76)                    | 0.04    | 1.98 (1.04 to 3.78)                    | 0.04    |
| Diabetes, yes/no               | 1.96 (1.18 to 3.26)                    | 0.01    | 1.96 (1.18 to 3.26)                    | 0.009   |
| Log_CRP,a per 1 unit           | 1.40 (1.13 to 1.73)                    | 0.001   | 1.42 (1.15 to 1.75)                    | 0.001   |
| SBP, per 10 mm Hg              | 1.19 (1.08 to 1.31)                    | 0.001   | 1.18 (1.08 to 1.31)                    | 0.001   |
| Albumin,a per 10 units         | 0.62 (0.40 to 0.95)                    | 0.03    | 0.59 (0.38 to 0.89)                    | 0.01    |
| Hemoglobin,a per 10 units      | 0.92 (0.77 to 1.10)                    | 0.35    |                                        |         |
| ESA,b per 100 units            | 1.00 (1.00 to 1.00)                    | 0.98    |                                        |         |
| IV iron dose,b per 100 units   | 0.97 (0.81 to 1.15)                    | 0.71    |                                        |         |

CRP, C-reactive protein; SBP, systolic BP; ESA, erythropoiesis-stimulating agent; IV, intravenous.

*aHemoglobin, ESA, and IV iron dose used for this analysis are time-varying variables on the basis of the most recent previous level over the postrandomization values for each variable during the trial.

*bHemoglobin, ESA, and IV iron dose used for this analysis are time-varying variables on the basis of the mean of previous levels over the postrandomization values for each variable during the trial.
proactive iron treatment regimen in renal anemia in patients on HD requiring ESA therapy.

Disclosures
S.D. Anker reports grants and personal fees from Abbott Vascular, grants and personal fees from Vifor Int, personal fees from Bayer, personal fees from Boehringer Ingelheim, personal fees from Impulse Dynamics, personal fees from Novartis, personal fees from Servier, and personal fees from SJM outside the submitted work. P.S. Jhund reports advisory board fees and grants from Boehringer Ingelheim, speakers and advisory board fees from AstraZeneca, and speakers and advisory board fees from Novartis. P.A. Kalra reports grants from BergenBio, grants and personal fees from Astellas, grants and personal fees from Vifor, personal fees from AstraZeneca, personal fees from Bayer, personal fees from Boehringer Ingelheim, personal fees from Mundipharma, personal fees from Napp, personal fees from Novonordisk, and personal fees from Pharmacosmos outside the submitted work. P.B. Mark reports grants from Boehringer Ingelheim; personal fees from Astellas, AstraZeneca, Janssen, and Novartis; and personal fees and nonfinancial support from Napp, Pharmacosmos, and Vifor outside the submitted work. I.C. Macdougall reports personal fees from GlaxoSmithKline and Vifor Pharma. The employer of J.J.V. McMurray, the University of Glasgow, has been remunerated by Abbvie, Amgen, AstraZeneca, Bayer, Bristol Myers and Squibb, Cardiorentis, DalCor, GlaxoSmithKline, Kidney Research UK, Merck, Novartis, Oxford University/Bayer, Pfizer, Theracos, and Vifor-Fresenius. M.C. Petrie reported receiving lecture fees from AstraZeneca and Eli Lilly during the conduct of the study and personal fees from AstraZeneca, NAPP Pharmaceuticals, Novo Nordisk, and Takeda. A. Power reports personal fees from Bayer GmBH and personal fees from Vifor Fresenius Renal Pharma outside the submitted work. D.C. Wheeler has an ongoing consultancy contract with AstraZeneca and has received honoraria from Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Janssen, Merck Sharp and Dohme, Mundipharma, Napp, Tricida, and Vifor Fresenius. C.G. Winearls is an employee of Pfizer. All remaining authors have nothing to disclose.

Funding
The PIVOTAL trial was funded by Kidney Research UK, which was supported by an unrestricted grant from Vifor Fresenius Medical Care Renal Pharma.

Author Contributions
I.C. Macdougall conceptualized the study; all authors were responsible for investigation; all authors were responsible for formal analysis; all authors were responsible for methodology; I. Ford and M. Robertson were responsible for project administration; I.C. Macdougall provided supervision; P.B. Mark wrote the original draft; and all authors reviewed and edited the manuscript.

Supplemental Material
This article contains supplemental material online at http://kidney360.asnjournals.org/lookup/suppl doi:10.34067/KID.0004272021/-/DCSupplemental.

Supplemental Material. Adjudication of stroke events and outcomes.

Supplemental Figure 1. Cumulative mortality following a first stroke event.

Supplemental Table 1. (a) Table of mean (SD) for baseline SBP by day of the week with P value from ANOVA and (b) by days of the week grouped to take account of dialysis shift (i.e., Monday/Tuesday as typically following the “long gap” between dialysis sessions) with P value from ANOVA.

Supplemental Table 2. Association between baseline clinical variables, laboratory data and post randomization stroke events in univariable (left) and multivariable models. In comparison with Table 4, hemoglobin here is the baseline value at randomization, with ESA dose similarly the dose at the time of randomization.

References
1. Findlay MD, Thomson PC, Fulton RL, Solbu MD, Jardine AG, Patel RK, Stevens KK, Gedeel CS, Dawson J, Mark PB: Risk factors of ischemic stroke and subsequent outcome in patients receiving hemodialysis. Stroke 46: 2477–2481, 2013 https://doi.org/10.1161/STROKEAHA.115.009955
2. Seliger SL, Gillen DL, Longstreth Jr. WT, Kestenbaum B, Stehman-Breen CO: Elevated risk of stroke among patients with end-stage renal disease. Kidney Int 64: 603–609, 2003 https://doi.org/10.1046/j.1523-1755.2003.00101.x
3. De La Mata NL, Masson P, Al-Shahi Salman R, Kelly PJ, Webster AC: Death from stroke in end-stage kidney disease. Stroke 50: 487–490, 2019 https://doi.org/10.1161/STROKEAHA.118.023644
4. Masson P, Kelly PJ, Craig JC, Lindley RI, Webster AC: Risk of stroke in patients with ESRD. Clin J Am Soc Nephrol 10: 1585–1592, 2015 https://doi.org/10.2215/CJN.12001214
5. Kelly DM, Rothwell PM: Prevention and treatment of stroke in patients with chronic kidney disease: An overview of evidence and current guidelines. Kidney Int 97: 266–278, 2020 https://doi.org/10.1016/j.kint.2019.09.024
6. Findlay MD, Dawson J, Dickie DA, Forbes KP, McGlynn D, Quinn T, Mark PB: Investigating the relationship between cerebral blood flow and cognitive function in hemodialysis patients. J Am Soc Nephrol 30: 147–158, 2019 https://doi.org/10.1681/ASN.2018050462
7. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, Murray JA, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R, TREAT Investigators: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361: 2019–2032, 2009 https://doi.org/10.1056/NEJMoa0907845
8. Singh AK, Szczepc L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D; CHOIR Investigators: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085–2098, 2006 https://doi.org/10.1056/NEJMoa062276
9. Druéke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A; CREATE Investigators: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071–2084, 2006 https://doi.org/10.1036/NEMo065485
10. Levin A, Djurdjevic O, Thompson C, Barnett B, Ethier J, Carlisle E, Barre P, Magner P, Mihurhead N, Tohe S, Tam P, Wadgymar JA, Kappel J, Holland D, Pichette V, Shoker A, Solys G, Verrelli M, Singer J; Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis 47: 878–887, 2006 https://doi.org/10.1053/j.ajkd.2005.08.007
11. Besarab A, Bolton WK, Browne JK, Egie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584–590, 1998 https://doi.org/10.1056/NEJM199808273390301
12. Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, Maggioni AP, McMurray JJ, O’Connor C, Pfeifer MA, Solomon SD, Sun Y, Tendera M, van Veldhuisen DJ; RED-HF Investigators; RED-HF Investigators: Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 368: 1210–1219, 2013 https://doi.org/10.1056/NEJMoa1214865
39. Murray AM, Seliger S, Lakshminarayan K, Herzog CA, Solid CA: Incidence of stroke before and after dialysis initiation in older patients. *J Am Soc Nephrol* 24: 1166–1173, 2013 https://doi.org/10.1681/ASN.2012080841

**Received:** June 28, 2021 **Accepted:** September 2, 2021

See editorial, “Untangling the Association between Anemia Treatment and Stroke Risk in CKD,” on pages 1693–1695.

*The PIVOTAL Investigators are Georgia Winnett, Habib Akbani, Julie Wessels, Waqar Ayub, Andrew Connor, Alison Brown, Jim Moriarty, Paramit Chowdury, Megan Griffiths, Indranil Dasgupta, Timothy Doulton, Jonathan Barratt, Enric Vilar, Sandip Mitra, Babu Ramakrishna, Johann Nicholas, Calum Ross, Arif Khwaja, Matt Hall, Adam Kirk, Stuart Smith, Mark Jesky, Clara Day, Bas sam Alchi, Jon Stratton, Helen Clarke, Stephen Walsh, Rebecca Brown, Kieran McCafferty, Laurie Solomon, Suresh Ramadoss, Babu Ramakrishna, Kolitha Basanyake, Sarah Lawman, Gowrie Balasubramaniam, Debasish Banerjee, Pauline Swift, Matt Wellberry-Smith, Christopher Goldsmith, Thomas Ledson, Ashraf Mikhail, Ruth Benzimra, Samira Bell, Alison Severn, John Neary, Arthur Doyle, Peter Thomson, Girish Shivashankar, Stephanie Bolton, Michael Quinn, Peter Maxwell, and John Harty.

**AFFILIATIONS**

1 Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom
2 Richard Bright Renal Unit, North Bristol NHS Trust, Bristol, United Kingdom
3 Department of Renal Medicine, King’s College Hospital, London, United Kingdom
4 Robertson Centre for Biostatistics, University of Glasgow, Glasgow, United Kingdom
5 Hull and East Yorkshire Hospitals NHS Trust and Hull York Medical School, Hull, United Kingdom
6 Department of Cardiology, Berlin-Brandenburg Center for Regenerative Therapies, German Center for Cardiovascular Research, Partner Site Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany
7 Lister Hospital, Stevenage, United Kingdom
8 Salford Royal Hospital and University of Manchester, Manchester, United Kingdom
9 Department of Renal Medicine, Freeman Hospital, Newcastle upon Tyne, United Kingdom
10 Department of Renal Medicine, University College London, London, United Kingdom
11 Oxford Kidney Unit, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom